Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

First Posted Date
2020-12-29
Last Posted Date
2022-09-08
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
84
Registration Number
NCT04687761
Locations
🇪🇸

Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Spain

🇪🇸

Hospital Clínic, Barcelona, Spain

🇪🇸

Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain

and more 12 locations

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2020-12-09
Last Posted Date
2024-01-08
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
63
Registration Number
NCT04659044
Locations
🇺🇸

Siouxland Regional Cancer Center, Sioux City, Iowa, United States

🇺🇸

Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States

🇺🇸

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

and more 2 locations

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

First Posted Date
2020-12-08
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
188
Registration Number
NCT04657081
Locations
🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States

🇺🇸

Boca Raton Clinical Research, Plantation, Florida, United States

and more 31 locations

Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

First Posted Date
2020-12-07
Last Posted Date
2024-08-26
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
52
Registration Number
NCT04655755
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

First Posted Date
2020-12-07
Last Posted Date
2022-06-09
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT04655391
Locations
🇺🇸

City of Hope Meidcal Center, Duarte, California, United States

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

First Posted Date
2020-11-13
Last Posted Date
2024-06-13
Lead Sponsor
University of Ulm
Target Recruit Count
650
Registration Number
NCT04628026
Locations
🇩🇪

Medizinische Hochschule Hannover, Hannover, Germany

🇩🇪

Charité Berlin - Campus Benjamin Franklin, Berlin, Germany

🇩🇪

Charité Berlin - Campus Mitte, Berlin, Germany

and more 9 locations

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

First Posted Date
2020-11-10
Last Posted Date
2024-12-04
Lead Sponsor
Genmab
Target Recruit Count
184
Registration Number
NCT04623541
Locations
🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 74 locations

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

Recruiting
Conditions
Chronic Lymphocytic Leukemia
Interventions
Drug: Venetoclax
First Posted Date
2020-11-04
Last Posted Date
2021-10-28
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
500
Registration Number
NCT04616274
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Venetoclax
First Posted Date
2020-11-03
Last Posted Date
2021-10-28
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
500
Registration Number
NCT04613622
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2020-10-29
Last Posted Date
2023-01-25
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
350
Registration Number
NCT04607772
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy